Genetic Investigation of Nordic Patients with Complement-mediated Kidney Diseases

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Sep 25

PMID 37744338

Authors

Viktor Rydberg

Sigridur Sunna Aradottir

Ann-Charlotte Kristoffersson

Naila Svitacheva

Diana Karpman

Affiliations

Soon will be listed here.

Abstract

Background: Complement activation in atypical hemolytic uremic syndrome (aHUS), C3 glomerulonephropathy (C3G) and immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) may be associated with rare genetic variants. Here we describe gene variants in the Swedish and Norwegian populations.

Methods: Patients with these diagnoses (N=141) were referred for genetic screening. Sanger or next-generation sequencing were performed to identify genetic variants in 16 genes associated with these conditions. Nonsynonymous genetic variants are described when they have a minor allele frequency of <1% or were previously reported as being disease-associated.

Results: In patients with aHUS (n=94, one also had IC-MPGN) 68 different genetic variants or deletions were identified in 60 patients, of which 18 were novel. Thirty-two patients had more than one genetic variant. In patients with C3G (n=40) 29 genetic variants, deletions or duplications were identified in 15 patients, of which 9 were novel. Eight patients had more than one variant. In patients with IC-MPGN (n=7) five genetic variants were identified in five patients. Factor H variants were the most frequent in aHUS and C3 variants in C3G. Seventeen variants occurred in more than one condition.

Conclusion: Genetic screening of patients with aHUS, C3G and IC-MPGN is of paramount importance for diagnostics and treatment. In this study, we describe genetic assessment of Nordic patients in which 26 novel variants were found.

Citing Articles

C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulation.

Heidenreich K, Goel D, Priyamvada P, Kulkarni S, Chakurkar V, Khullar D Front Nephrol. 2024; 4:1460146.

PMID: 39534179 PMC: 11554616. DOI: 10.3389/fneph.2024.1460146.

Extrarenal manifestations in inherited kidney diseases.

Hoefele J, Eble J, Hermle T, Wuttke M, Schultheiss U Nephrol Dial Transplant. 2024; 40(2):227-233.

PMID: 39096159 PMC: 11792654. DOI: 10.1093/ndt/gfae176.

Complement dysregulation associated with a genetic variant in factor H-related protein 5 in atypical hemolytic uremic syndrome.

Aradottir S, Kristoffersson A, Linner E, Karpman D Pediatr Nephrol. 2023; 39(4):1105-1111.

PMID: 37955705 PMC: 10899364. DOI: 10.1007/s00467-023-06184-6.

References

Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang W, le Quintrec M . Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531-6. PMC: 3719402. DOI: 10.1038/ng.2590. View

Szarvas N, Szilagyi A, Csuka D, Takacs B, Rusai K, Muller T . Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome. Mol Immunol. 2016; 71:10-22. DOI: 10.1016/j.molimm.2016.01.003. View

Aradottir S, Kristoffersson A, Jensson B, Sulem P, Gong H, Palsson R . Factor B Mutation in Monozygotic Twins Discordant for Atypical Hemolytic Uremic Syndrome. Kidney Int Rep. 2023; 8(5):1097-1101. PMC: 10166735. DOI: 10.1016/j.ekir.2023.02.1069. View

Sartz L, Olin A, Kristoffersson A, Stahl A, Johansson M, Westman K . A novel C3 mutation causing increased formation of the C3 convertase in familial atypical hemolytic uremic syndrome. J Immunol. 2012; 188(4):2030-7. DOI: 10.4049/jimmunol.1100319. View

Garam N, Cserhalmi M, Prohaszka Z, Szilagyi A, Veszeli N, Szabo E . FHR-5 Serum Levels and Genetic Variations in Patients With Immune Complex-Mediated Membranoproliferative Glomerulonephritis and C3-Glomerulopathy. Front Immunol. 2021; 12:720183. PMC: 8461307. DOI: 10.3389/fimmu.2021.720183. View

Urban A, Volokhina E, Felberg A, Stasilojc G, Blom A, Jongerius I . Gain-of-function mutation in complement C2 protein identified in a patient with aHUS. J Allergy Clin Immunol. 2020; 146(4):916-919.e11. DOI: 10.1016/j.jaci.2020.02.014. View

Fang C, Fremeaux-Bacchi V, Liszewski M, Pianetti G, Noris M, Goodship T . Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2007; 111(2):624-32. PMC: 2200836. DOI: 10.1182/blood-2007-04-084533. View

Schmitt R, Krmar R, Kristoffersson A, Soderberg M, Karpman D . IgA nephropathy associated with a novel N-terminal mutation in factor H. Eur J Pediatr. 2010; 170(1):107-10. DOI: 10.1007/s00431-010-1279-3. View

Urban A, Kowalska D, Stasilojc G, Kuzniewska A, Skrobinska A, Arjona E . Gain-of-Function Mutations R249C and S250C in Complement C2 Protein Increase C3 Deposition in the Presence of C-Reactive Protein. Front Immunol. 2021; 12:724361. PMC: 8654806. DOI: 10.3389/fimmu.2021.724361. View

10.

Vaziri-Sani F, Holmberg L, Sjoholm A, Kristoffersson A, Manea M, Fremeaux-Bacchi V . Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int. 2006; 69(6):981-8. DOI: 10.1038/sj.ki.5000155. View

11.

Sethi S, Fervenza F . Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012; 366(12):1119-31. DOI: 10.1056/NEJMra1108178. View

12.

Mohlin F, Nilsson S, Levart T, Golubovic E, Rusai K, Muller-Sacherer T . Functional characterization of two novel non-synonymous alterations in CD46 and a Q950H change in factor H found in atypical hemolytic uremic syndrome patients. Mol Immunol. 2015; 65(2):367-76. DOI: 10.1016/j.molimm.2015.02.013. View

13.

Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey M, Ngo S . Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8(4):554-62. PMC: 3613948. DOI: 10.2215/CJN.04760512. View

14.

PETERS D, Martin A, Weinstein A, Cameron J, BARRATT T, Ogg C . Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol. 1972; 11(3):311-20. PMC: 1553661. View

15.

El Sissy C, Rosain J, Vieira-Martins P, Bordereau P, Gruber A, Devriese M . Clinical and Genetic Spectrum of a Large Cohort With Total and Sub-total Complement Deficiencies. Front Immunol. 2019; 10:1936. PMC: 6694794. DOI: 10.3389/fimmu.2019.01936. View

16.

Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C . Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. J Am Soc Nephrol. 2017; 29(1):283-294. PMC: 5748907. DOI: 10.1681/ASN.2017030258. View

17.

Corvillo F, Okroj M, Nozal P, Melgosa M, Sanchez-Corral P, Lopez-Trascasa M . Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Front Immunol. 2019; 10:886. PMC: 6491685. DOI: 10.3389/fimmu.2019.00886. View

18.

Sadovnick A, Traboulsee A, Bernales C, Ross J, Forwell A, Yee I . Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3 (Bethesda). 2016; 6(7):2073-9. PMC: 4938660. DOI: 10.1534/g3.116.030841. View

19.

Zipfel P, Mache C, Muller D, Licht C, Wigger M, Skerka C . DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol. 2010; 25(10):2009-19. DOI: 10.1007/s00467-010-1446-9. View

20.

Marinozzi M, Vergoz L, Rybkine T, Ngo S, Bettoni S, Pashov A . Complement factor B mutations in atypical hemolytic uremic syndrome-disease-relevant or benign?. J Am Soc Nephrol. 2014; 25(9):2053-65. PMC: 4147975. DOI: 10.1681/ASN.2013070796. View